Image

Evaluation of the Use of Sitagliptin for Insulin Resistance in Burn Patients

Objective

This retrospective review compares exogenous insulin requirements before and after sitagliptin initiation as well as time to liberation from intravenous insulin infusion (managed with EndoTool) for patients admitted to a burn intensive care unit.

Setting

Largest (425-bed) U.S. military hospital, academic medical center and Level 1 trauma center.

Results
  • Median exogenous insulin requirements decreased 68.2% after sitagliptin initiation, from 114.3 to 36.3 units/day.
  • Incidence of hyperglycemia >180 mg/dL decreased 15% after sitagliptin initiation, from 90.9% to 77.3% of patients.
  • Incidence of hypoglycemia <70 mg/dL decreased 33% after sitagliptin initiation, from 13.6% to 9.1% of patients.
  • Median time to liberation from intravenous insulin infusion was 3 days after sitagliptin initiation.
Conclusions

The addition of sitagliptin as an adjunct anti-hyperglycemic agent following burn injury is associated with a reduction in exogenous insulin requirements as well as a reduction in episodes of hyperglycemia and hypoglycemia, and allows liberation from intravenous insulin infusion (managed with EndoTool) over a 3-day period.

Authors

Kaitlin Pruskowski; Beth Shield; Craig Ainsworth; Leopoldo Cancio.

Source

Published in International Journal of Burns and Trauma, Volume 10, Issue5, p237-245.

Year

2020